Hormone receptor +ve advanced breast cancer in postmenopausal women. Adjuvant treatment of hormone receptor +ve early invasive breast cancer in postmenopausal women who have received 2-3 yr of adjuvant tamoxifen.
Not to be used in premenopausal women. May reduce bone mineral density w/ possible consequent increased risk of fracture. Assess bone mineral density regularly on women w/ or at risk of osteoporosis. Not to be taken by patients w/ rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Avoid co-administration w/ tamoxifen or estrogen-containing therapies. Moderate & severe hepatic impairment. Severe renal impairment (GFR <30 mL/min). Not recommended for use in childn & adolescents.
Sign Out
